Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
about
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromesIdebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?Therapeutic developments in Friedreich ataxiaFriedreich's ataxia: the vicious circle hypothesis revisited.Therapies in inborn errors of oxidative metabolism.Co-enzyme Q10 and idebenone use in Friedreich's ataxia.Consensus paper: management of degenerative cerebellar disorders.Friedreich ataxia in Norway - an epidemiological, molecular and clinical studyRating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database.Drug development for rare mitochondrial disordersReview of clinical trials for mitochondrial disorders: 1997-2012.Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.Bioenergetic medicine.A review of Friedreich ataxia clinical trial results.Recent advances in clinical neurogenetics.Hereditary ataxias: overview.Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.Treatable causes of cerebellar ataxia.Age-related reference values for the pediatric Scale for Assessment and Rating of Ataxia: a multicentre study.Therapeutic approaches for the treatment of Friedreich's ataxia.Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids.IGF-1 in Friedreich's Ataxia - proof-of-concept trialSeeking a better landscape for therapy development in neuromuscular disorders.Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial.Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial.Vitamin K: a structural basis for the design of novel neuroprotective agents?Frataxin silencing alters microtubule stability in motor neurons: implications for Friedreich's ataxia.Idebenone in Friedreich ataxia and Leber's hereditary optic neuropathy: close mechanisms, similar therapy?Emerging therapeutics for the treatment of Friedreich’s ataxiaTowards a therapy for mitochondrial disease: an update
P2860
Q24193064-BB96C472-12AD-48DF-8DCC-27B48BE28006Q26853254-E11173C1-9ADB-45A7-8D9A-C68690157B4BQ26861733-C1B60E08-1651-4A3A-B3E1-DEE79ECD6BACQ34045081-F6D4C415-9303-433D-B3C9-AE6207FE3EC5Q34055267-C18F3056-31FA-40C5-85A8-364511730C4CQ34654338-86865889-9746-4DFF-99E5-8081AFAA1AAEQ35129909-2311361C-42A6-4DDA-927A-4895B529235BQ35764226-FC33EAAB-CFDF-4A96-A3F6-E214DAE7C514Q36760861-26CEAAC5-627D-44EF-92FA-EB2D8D1937DFQ36762826-B20CA0BD-C75D-4BDC-890C-585AB101C325Q36762846-65CBD0BF-00AA-4FBD-9ED8-E3F3EA4C4C4EQ37095593-C2D6DE12-5B05-4898-A62F-559CED66ED11Q37686246-B675BE44-6FDD-4849-8366-4363CB4D8DB2Q38038592-DAAF65E5-AD8B-449D-A8F0-682055D2DC40Q38060657-F5A88B37-7F90-44E7-A8BC-D43B0D1C73D7Q38094029-258F38FA-0794-464C-95EE-E5357F7F82E2Q38121949-1F0F46D6-3CAB-4959-91EC-B1D695699BC4Q38372235-1033E372-116B-4405-BED2-2AE774B2ADADQ38620939-CFA8502E-81D1-449A-BCED-7C4FA01F63A1Q39158402-C3C0C366-52CC-4B02-B21B-6EC6E08A573CQ39330763-C745D2FF-875A-494C-8DD4-90DCA20B552CQ41856841-1CF1DA5E-758E-495F-BD85-A0207C3C43E3Q42688781-E1F9793A-4573-48CE-8617-8C78154D182CQ44841982-1B0BC013-6EF9-41D4-99D7-086B2492A66DQ44994050-B630ADB7-4E14-4C89-A86E-253373EEE89CQ45769190-357866C7-5CC7-4CBC-A068-67BADAF2E316Q51575796-61BE0FF1-A634-44A8-832B-C50A239D3EF3Q54292903-F546D337-DC10-4157-8BD6-4C7DB952EBA0Q56700247-51D2B4BC-E42E-4FFD-B0C2-5E7A07638B09Q57293416-BFAA38E6-D286-479B-99A3-C4676E67E1C0
P2860
Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Assessment of neurological eff ...... th open-label extension study.
@ast
Assessment of neurological eff ...... th open-label extension study.
@en
type
label
Assessment of neurological eff ...... th open-label extension study.
@ast
Assessment of neurological eff ...... th open-label extension study.
@en
prefLabel
Assessment of neurological eff ...... th open-label extension study.
@ast
Assessment of neurological eff ...... th open-label extension study.
@en
P2093
P2860
P1433
P1476
Assessment of neurological eff ...... th open-label extension study.
@en
P2093
David R Lynch
Nicholas J Coppard
Susan L Perlman
Thomas Meier
P2860
P2888
P304
P356
10.1007/S00415-011-6174-Y
P577
2011-07-22T00:00:00Z
P6179
1020035703